• about
  • Our Technologies
    • Multi-Chimeric Cell platform
      • Duchenne Dystrophy
      • Sickle Cell Disease
      • Anti-Aging
  • Press
  • Pipeline
  • Executive Team
  • Contact us
  • Szukaj
Dystrogen Therapeutics Corporation
Dystrogen Therapeutics Corporation
Przejdź do treści
  • about
  • Our Technologies
    • Multi-Chimeric Cell platform
      • Duchenne Dystrophy
      • Sickle Cell Disease
      • Anti-Aging
  • Press
  • Pipeline
  • Executive Team
  • Contact us
  • Szukaj

Executive Team

Executive Team

 

 

 

Maria Siemionow
MD, PhD, Founder and Chief Scientific Officer

 

 

 

 

 

Kris Siemionow
MD, PhD, Co-Founder and CEO

 

 

 

Paul Lewicki
PhD, Co-Founder and Board Member

 

 

 

Edyta Niemczyk
PhD, Chief Operating Officer, Regulatory Affairs Expert

 


Marta Osęka
Vice President of Business Development and Investor Relations

 

 

Marcin Zając
Financial Controller

 

 

 

 

 

 

CELL-BASED THERAPIES

Duchenne Muscular Dystrophy

Dystrophin Expressing Chimeric Cells (DEC) based therapy developed by Dystrogen Therapeutics aims to target all patients suffering from Duchenne muscular dystrophy, irrespective of existing genetic mutation.

| READ MORE |

Sickle Cell Disease

Dystrogen Therapeutics has developed new multi-chimeric cells for treating patients with Sickle Cell Diseases. Our multi chimeric cells are created via cell fusion of 3 or more cells of hematopoietic origin from three different donors...

| READ MORE |

US Headquarters:

Dystrogen Therapeutics Corporation
1415 W 37th Street
Chicago, Illinois

EU R&D:
Dystrogen Therapeutics
ul. Kasztelańska 49
Poznań 60-316, PL
NIP: 7792482313

General inquiries:
info@dystrogen.com

 

Investor Relations Contacts:
investors@dystrogen.com

Information

About
Executive Team
Our Technologies
Pipeline
Investor Relations
Contact us

©2019 Dystrogen Therapeutics Corporation
Back to Top